Amgen at PSMB5
As of the edition of 20 October 2026, Amgen is on route B at PSMB5 (proteasome subunit beta type-5), position 10 of 2,016 on that route, with a score of 0.785.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.785
Biology proven in humans0.79
How much the company cares0.91
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Active at the target or its disease area recently+0.183
Few other companies active at the target+0.128
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
Trials at the target more often meet than miss their main endpoint0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 20 October 2026.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 20 July 2012.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 20 July 2012.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Carfilzomib | Marketed | Phase 4 | 229 | Exclusivity ends: 22 November 2028 |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT03512353 | Carfilzomib | Phase 2 | Terminated | 2018 to 2020 | 7 | No results posted |
| The registry records: “Sponsor Decision” | ||||||
| NCT04191616 | Carfilzomib | Phase 2 | Completed | 2020 to 2024 | 54 | No results posted |
| NCT03934684 | Carfilzomib | Phase 4 | Completed | 2019 to 2025 | 101 | No results posted |
| NCT03158688 | Carfilzomib | Phase 3 | Completed | 2017 to 2022 | 466 | Main endpoint met |
| NCT02412878 | Carfilzomib | Phase 3 | Completed | 2015 to 2019 | 478 | Main endpoint met |
| NCT02335983 | Carfilzomib | Phase 1 | Completed | 2015 to 2019 | 107 | No results posted |
| NCT02303821 | Carfilzomib | Phase 1 | Completed | 2015 to 2024 | 141 | Result could not be read |
| NCT01949532 | Carfilzomib | Phase 1 | Completed | 2014 to 2017 | 26 | Result could not be read |
| NCT01987232 | Carfilzomib | Phase 1/2 | Completed | 2013 to 2017 | 32 | No results posted |
| NCT01949545 | Carfilzomib | Phase 1 | Completed | 2013 to 2015 | 46 | Mixed result |
| NCT01980589 | Carfilzomib | Phase 1 | Completed | 2013 to 2016 | 22 | No results posted |
| NCT01818752 | Carfilzomib | Phase 3 | Completed | 2013 to 2016 | 955 | Main endpoint missed |